Financial StabilityThe company's cash runway has been extended into the fourth quarter of 2027, providing financial stability for future operations.
Pipeline ExpansionCNTY-308, a next-generation CD19-directed CAR-T candidate for B-cell mediated diseases, has entered Investigational New Drug (IND)-enabling studies.
Product DevelopmentCNTY-101 is seen as a differentiated product for autoimmune disease given its strong safety profile and potentially reduced lymphodepletion requirements.